Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Case Studies / Patient 2a: Stage 2 NK in the left eye

Patient 2a: Stage 2 NK in the left eye3,4

Teaser paragraph required

1/1/0001 6 min read

Share

Images show a neurotrophic corneal lesion from baseline through week 8 of an actual patient treated with OXERVATE® in a pivotal clinical trial. This is 1 patient’s outcome. Results are not indicative of all patients in the clinical trial.

BASELINE

Patient Overview

Images are of a clinical trial patient with Stage 2 neurotrophic keratitis (NK) at baseline and week 8. Evaluations conducted by independent central reading center of the clinical images of corneal fluorescein staining. Not all patients in the trials achieved complete corneal healing. Individual results may vary.1,2


Images show a neurotrophic corneal lesion from baseline through week 8 of an actual patient treated with OXERVATE® in a pivotal clinical trial. This is 1 patient’s outcome. Results are not indicative of all patients in the clinical trial.

WEEK 8

Patient Overview

Images are of a clinical trial patient with Stage 2 neurotrophic keratitis (NK) at baseline and week 8. Evaluations conducted by independent central reading center of the clinical images of corneal fluorescein staining. Not all patients in the trials achieved complete corneal healing. Individual results may vary.1,2


Patient 2a4

Patient information*

33-year-old female

Eye: Left, OS

Treatment-related adverse events†

None4

† As recorded by the investigator; relationship to study treatment recorded as possible, probable, or highly probable.

Study

NGF0214

Investigator-determined etiology

Herpes zoster virus and diabetes

Diagnosis

NK Stage 2

Evaluation of complete corneal healing

Complete corneal healing, defined as absence of staining of the corneal lesion and no persistent staining in the rest of the cornea, at 8 weeks of treatment.3,5

IMPORTANT NOTE: Each clinical trial participant's experience on treatment is unique. Individual results may vary.

*The information depicted is what was collected as part of the requirements of the clinical trials. This is not an all-inclusive medical history of the patient.1,2

      Download the Case Study as a PDF     


OXERVATE® is indicated for the treatment of neurotrophic keratitis.

Important Safety Information

WARNINGS AND PRECAUTIONS

Use with Contact Lens
Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.
Please read the full Prescribing Information for OXERVATE, available from your Dompé representative.

Related Content

Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational Ophthalmology can take rare disease diagnostics to the next level

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

Thank you for reading
The Ophthalmologist

To continue reading, either register for a free account below or login.

Register or Login

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: